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Objectives. We sought to assess the effects of second-hand
smoke (SHS) and gender on infarct size in young rats exposed in
utero or in the neonatal to adolescent period, or both.
Background. We previously demonstrated that exposure to SHS
increases infarct size in a rat model of ischemia and reperfusion,
with a dose-response relation. These results are consistent with
epidemiologic studies demonstrating that SHS increases risk of
death from heart disease.
Methods. Thirty-one pregnant female rats were randomly di-
vided into two groups: those exposed to SHS and a control group
(non-SHS). After 3 weeks, each rat had given birth to 10 to 12 rats.
One hundred one neonatal rats were divided into four groups
according to exposure to SHS in utero (SHSu) and randomized to
SHS exposure in the neonatal to adolescent period (SHSna). After
12 weeks, all rats were subjected to 17 min of left coronary artery
occlusion and 2 h of reperfusion.
Results. Birth mortality was higher in the SHSu group than in
the non-SHSu group (11.9% vs. 2.8%, p < 0.001). Body weight of
neonatal rats at 3 and 4 weeks in the two SHSu groups was lower
than that of rats in the two non-SHSu groups (p < 0.001).
Exposure to SHSna increased endothelin-1 levels in plasma (p 5
0.001). In all 70 young rats who survived the neonatal period, infarct
size (Infarct mass/Risk area 3 100%) was greater in the SHSna
groups than in the non-SHSna groups (p 5 0.005) and in the male
groups than in the female groups (p < 0.001).
Conclusions. Exposure to SHS in the neonatal to adolescent
period and male gender increased myocardial infarct size in a
young rat model of ischemia and reperfusion. These results are
consistent with epidemiologic studies demonstrating that SHS
increases the health risk to neonates and adolescents.
(J Am Coll Cardiol 1997;30:1878–85)
©1997 by the American College of Cardiology
The health consequences of involuntary exposure to second-
hand smoke (SHS) have been a subject of intense scientific and
public health concern (1,2). Many studies have shown a
relation between maternal smoking during pregnancy and an
increased prevalence of acute and chronic respiratory disor-
ders in childhood (3–5). In addition, maternal cigarette smok-
ing during pregnancy has been associated with increased
perinatal mortality and low birth weight (6,7). As with active
smoking, passive maternal exposure to tobacco smoke (invol-
untary maternal smoking) during pregnancy is also associated
with an increased incidence of asthma and a risk for patterns of
negative developmental outcomes (8). Passive smoking and
tobacco exposure through breast milk increases the risk of
sudden infant death syndrome in infants (9).
Epidemiologic and clinical studies have shown that SHS
causes heart disease in nonsmokers (10–12). It has been
estimated that SHS contributes to 37,000 deaths from heart
disease of the total 53,000 annual deaths, making passive
smoking the third leading preventable cause of death, after
active smoking and alcohol (10). The American Heart Associ-
ation has formally concluded that passive smoking is an
important risk factor for heart disease in both adults and
children (13,14). Of the thousands of chemicals in SHS, those
that are suspected to contribute to passive smoking-induced
cardiovascular disease include nicotine, carbon monoxide,
polycyclic aromatic hydrocarbons and tobacco glycoproteins
(10). Passive smoking may exacerbate acute myocardial isch-
emia by increasing coronary vasoconstriction and reducing
coronary blood flow, releasing catecholamines and increasing
myocardial oxygen demand, increasing oxygen free radical
generation and enhancing thrombosis (10–12).
A previous study from our group (15) showed that exposure
to SHS increased myocardial infarct size with a dose-response
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relation in adult female rats subjected to acute ischemia and
reperfusion. The effect of gender on infarct size in this model
is unclear. We previously showed that the male sex hormone,
testosterone, exacerbates the adverse vascular effects of SHS in
atherosclerotic rabbits (16). We therefore hypothesized that
the effects of SHS on myocardial ischemia would be greater in
male rats. We also investigated whether SHS exposure in utero
alone affects infarct size and whether its effect is additive to
SHS exposure in the neonatal to adolescent period.
In this study, we evaluated the effects of SHS on male and
female rats exposed in utero (3 weeks) and in the neonatal to
adolescent period (12 weeks). To further examine potential
mechanisms underlying the pro-ischemic effects of SHS, we
also measured levels of endothelin-1 and angiotensin-2, agents
known to induce coronary vasoconstriction.
Methods
Experimental groups. Thirty-one pregnant Sprague-
Dawley rats were randomly divided into SHS and non-SHS
groups, as described subsequently. Four Marlboro filter ciga-
rettes were smoked every 15 min for 6 h/day, 5 days/week, and
the SHS-exposed rats breathed the SHS that these cigarettes
produced. These 96 cigarettes/day were smoked using a smok-
ing machine (RM 1/G, Heinr Borgwald GmbH, Hamburg,
Germany), as previously described (17). The rats were housed
in separate cages in 1.92 3 1.92 3 0.97 m (3.6 m3), well mixed
SHS exposure chambers (model H 5500, BioClean, Duo Flo,
Lab Product Inc.). The exposure chamber had an interior
volume of 3.6 m3, similar to that of an automobile sedan (3.7 m3).
The average concentrations of air nicotine and carbon mon-
oxide, using this protocol, have been previously shown (17) to
be about twofold higher than those in heavy smoking environ-
ments of humans (12,15). The rats were housed in a room
maintained at a constant temperature and kept on a 12-h
light–dark cycle. All rats were fed a regular diet. After 3 weeks
of exposure in utero, each pregnant rat had given birth to
about 10 to 12 neonatal rats. The 101 neonatal rats were
divided into four groups—SHS and non-SHS groups—
according to SHS exposure in utero (3 weeks before birth) and
randomized to exposure in the neonatal (4 weeks after birth)
to adolescent (6 to 12 weeks after birth) period. The neonatal
and adolescent periods were grouped together because the
heart size of neonatal rats was too small to establish a reliable
infarct model.
The groups were as follows: SHSu/SHSna 5 exposed to
SHS in utero for 3 weeks and in the neonatal to adolescent
period for 12 weeks; SHSu/non-SHSna 5 exposed to SHS in
utero for 3 weeks only; non-SHSu/SHSna 5 exposed to SHS in
the neonatal to adolescent period for 12 weeks only; non-
SHSu/non-SHSna 5 not exposed in utero or in the neonatal to
adolescent period. The rats were then divided into eight groups
according to gender, which could be clearly identified at 3 to 4
weeks after birth.
Rat model of acute myocardial ischemia and reperfusion.
A rat model of left coronary artery occlusion and reperfusion
was used as previously described (18). All of the following
procedures were conducted in room air in a laboratory away
from the SHS exposure chamber. After induction of anesthesia
(pentobarbital, 40 mg/kg body weight intraperitoneally), a
tracheostomy was performed and the animal was ventilated on
a Harvard Rodent Respirator (model 683, Harvard Appara-
tus). A reversible coronary artery snare occluder was placed
around the proximal left anterior descending coronary artery
(LAD) through a midline sternotomy. All four groups were
subjected to 17 min of LAD occlusion followed by 120 min of
reperfusion. Throughout the study, body core temperature was
monitored with a rectal thermometer (Digital Thermometer,
Fisher Scientific Inc.). All rats were placed on a heating pad
(Deltaphase Isothermal Pad, model 39 DP, Braintree Scientific
Inc.) for the duration of the experiment. Body core tempera-
ture ranged from 36° to 37°C during the experiment.
Infarct size. Infarct size was measured as described previ-
ously (17–19). The left coronary artery was reoccluded, and
phthalocyanin blue dye was injected into the left ventricular
(LV) cavity, allowing normally perfused myocardium to stain
blue. The heart was then excised, rinsed of excess dye and
sliced transversely from apex to base into 2-mm-thick sections.
The sections were incubated in a 1% solution of triphenyltet-
razolium chloride for 10 to 15 min until viable myocardium was
stained brick red. Infarct-related myocardium fails to stain with
triphenyltetrazolium chloride. The tissue sections were then
fixed in a 10% formalin solution and weighed. Color digital
images of both sides of each transverse slice were obtained
with a videocamera (COHU Y/C 460 HTYL, 768 3 494 array,
Leica) connected to a microscope (Stereo Zoom 6 photo
Leica) using the Rasterops Frame Grabber card and Frame
Grabber 3.2 software (Rasterops). The regions showing blue-
stained (nonischemic), red-stained (ischemic but noninfarcted)
and unstained (infarcted) tissue were outlined on each color
image and measured using the program NIH Image 1.59
(National Institutes of Health) in a blinded fashion. On each
side, the fraction of LV area representing infarct-related tissue
(average of two images) was multiplied by the weight of that
section to determine the absolute weight of infarct-related
tissue. The infarct size for each heart was expressed as:
Infarct size/LV mass ~%! 5
O Infarct weight in each slice
Total LV weight
3 100%,
Abbreviations and Acronyms
ANOVA 5 analysis of variance
LAD 5 left anterior descending coronary artery
LV 5 left ventricular
Non-SHS 5 not exposed to second-hand smoke
SHS 5 second-hand smoke
SHSna 5 exposed to SHS in the neonatal to adolescent period
SHSu 5 exposed to SHS in utero
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Risk area/LV mass ~%! 5
Total weight of unstained section
Total LV weight
3 100%,
Infarct size as a percentage of risk area was then calculated as
O Infarct weight in each slice
ORisk area weight of each slice 3 100%.
Biochemical and hematologic analyses. A subset of the
neonatal rats (n 5 26; 6 or 7 selected at random from each
group) had blood samples withdrawn from the right atrium
to measure plasma nicotine, cotinine, endothelin-1 and
angiotensin-2 concentrations. The plasma concentrations of
nicotine and cotinine were determined by gas chromatography
with nitrogen-phosphorus detection. This method has been
modified for simultaneous extraction and determination of
cotinine by use of capillary gas chromatography (20). The
plasma levels of endothelin-1 and angiotensin-2 were mea-
sured by radioimmunoassay (Phoenix Pharmaceuticals, Inc.)
(21,22).
Statistical analysis. The results are presented as the mean
value 6 SEM. Data on plasma nicotine and cotinine concen-
trations in SHS and non-SHS groups were compared using the
Mann-Whitney rank-sum test. Differences in birth mortality or
mortality during the occlusion and reperfusion period between
two and four groups were assessed by the chi-square test.
Two-way analysis of variance (ANOVA) was used for most
comparisons in the study; the two factors are the presence or
absence of SHS exposure in the neonatal to adolescent period
(12 weeks) and SHS exposure in utero (3 weeks). For analysis
of the effect of gender, we used a three-factor ANOVA, with
gender (male or female) as the third grouping factor. All
computations were done with the general linear model proce-
dure in Minitab, version 7.2 (Minitab Statistical Software) or
Primer of Biostatistics: The Program, version 3.03 (McGraw-
Hill). Statistical significance was set at p , 0.05.
Results
Mortality and body weight. The birth mortality of the
groups exposed to SHS in utero was higher than that of control
(non-SHS) groups (11.9% vs. 2.8%, p , 0.001) (Fig. 1). The
neonatal body weights at 3 weeks and 4 weeks after birth in the
same groups exposed to SHS in utero were lower than those in
non-SHS exposure groups (p , 0.001) (Fig. 2). In addition,
SHS exposure during the neonatal period also decreased body
weight (p , 0.001) (Fig. 2). The gender of the rats could be
identified clearly only at 3 to 4 weeks after birth. After 12
weeks of exposure to SHS, the body weight of male rats was
higher than that of female rats (308 6 7 vs. 200 6 3 g, p ,
0.001). Exposure to SHS in the neonatal to adolescent period
for 12 weeks had no significant effect on body weight (p 5
0.523). Thirty-one rats died during the occlusion and reperfu-
sion period. The mortality of the male and female rats during
the ischemia and reperfusion period was similar—31% and
30%, respectively. The observed mortality in the groups ex-
posed to SHS in the neonatal to adolescent period for 12 weeks
was higher than that in the non-SHS groups (37% vs. 24%, p 5
0.273), but this difference was not statistically significant. Data
from the 70 surviving young rats were analyzed for infarct size.
Myocardial infarct size. Exposure to SHS in the neonatal
to adolescent period for 12 weeks significantly increased infarct
size (infarct mass/risk area 3 100%; p 5 0.005), especially in
female rats (Fig. 3, Table 1). Male gender also increased
infarct size in both SHS- and non–SHS-exposed groups (p ,
0.001) (Fig. 3, Table 1). Exposure to SHS in utero for 3 weeks
tended to increase infarct size (p 5 0.082), especially in female
rats (Fig. 3, Table 1). There were no significant interactions
(Table 1), indicating that these effects are additive. The results
are qualitatively similar for infarct size as a percentage of LV
mass, except that there is an interaction between in utero
exposure and gender. The risk areas for myocardial infarction
were similar among all groups (Table 1).
Biochemical and hematologic analyses. Plasma nicotine
and cotinine concentrations in the SHSna groups were higher
than those in the non-SHSna groups (39 6 5 ng/ml vs.
undetectable level [i.e., ,0.01 ng/ml], p , 0.0001 and 437 6
124 ng/ml vs. undetectable level [i.e., ,0.1 ng/ml], p , 0.0001,
respectively) (Fig. 4). Endothelin-1 levels in SHS-exposed
neonatal rats were higher than those in non–SHS-exposed
neonatal rats (for SHSna, p 5 0.001) (Fig. 5). Angiotensin-2
levels in neonatal rats exposed to SHS in utero were lower than
Figure 1. Birth mortality of newborns in the SHS-exposed in utero
group (SHSu) is higher than that of newborns not exposed in utero
(non-SHSu). The duration of exposure to SHS in utero was about 3
weeks. The p value was derived from the chi-square test.
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those in non–SHS-exposed neonatal rats (for SHSu, p 5 0.041)
(Fig. 6).
Discussion
We hypothesized that the effects of SHS on myocardial
ischemia would be larger in male rats and SHS exposure in
utero would increase infarct size, an effect additive to SHS
exposure in the neonatal to adolescent period.
The salient findings in this study were 1) exposure to SHS in
pregnant rats significantly increased birth mortality and de-
creased neonatal body weight; 2) infarct size in male rats was
larger than that in female rats in both SHS- and non–SHS-
exposed groups; 3) exposure to SHS in the neonatal to
adolescent period increased infarct size in young rats, espe-
cially in young female rats; 4) exposure to SHS in the neonatal
period increased plasma endothelin-1 levels; and 5) exposure
to SHS in utero tended to increase infarct size in young rats.
Birth mortality, body weight and SHS exposure. Clinical
studies (6,7) have noted that SHS doubles the risk of delivering
a low birth weight baby. Additional consequences to the
offspring of involuntary smoke exposure by nonsmoking preg-
nant women include reduced fetal growth and higher perinatal
mortality. The results of our study are consistent with these
findings. Only 3 weeks of exposure to SHS in pregnant rats
significantly increased birth mortality and decreased body
weight in neonatal rats. Although previous studies have linked
maternal smoking or exposure to SHS with impairment of
newborn pulmonary function (23–25), hematopoietic malig-
nancies (26), brain tumors (27) and DNA damage in the
placenta, little is known about the cardiovascular effects of
maternal exposure to SHS on the offspring. One clinical study
(28) noted that a potent tobacco-related carcinogen, 4-
aminobiphenyl, crosses the human placenta and binds to fetal
hemoglobin in significantly higher concentrations in smokers
than nonsmokers.
Infarct size and SHS exposure. The present study has
shown that SHS exposure in utero for 3 weeks tended to
increase infarct size in young rats, especially in young female
rats. Exposure to SHS in utero tended to increase infarct size
(p 5 0.082); the failure to reach conventional statistical
significance may be because the duration of exposure was too
short (only 90 h spread over 3 weeks) and the interval of 12
weeks between exposure in utero to making the infarct was too
long. A clinical study also showed that the adverse effect of
maternal smoking on lung function was greater on female
infants than on male infants (25). The present study also
showed that SHS exposure in the neonatal to adolescent
Figure 2. In the four groups, this profile plot shows (top)
the body weight of neonates at 3 weeks after birth and
(bottom) the body weight of neonates at 4 weeks after
birth. Data are presented as mean value 6 SEM. Non-
SHSna 5 newborn rats not exposed to SHS in the
neonatal period; SHSna 5 newborn rats exposed to SHS
in the neonatal period; non-SHSu 5 mother rat not
exposed to SHS in utero; SHSu 5 mother rat exposed to
SHS in utero for 3 weeks. The p values were derived from
two-way ANOVA.
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period (12 weeks after birth) significantly increased infarct
size, especially in young female rats. This result is consistent
with our previous study (15), although there were four differ-
ences in the protocols used. First, the occlusion period was
reduced from 35 to 17 min in the present study. Second, the
SHS exposure duration was increased from 6 to 12 weeks. We
increased the SHS exposure duration, because newborn rats
were too small to technically achieve a reproducible infarct
model. Third, the rats in the present study were younger than
those in previous studies. Fourth, we used a color digital
imaging system with specialized software to measure infarct
size instead of our previous approach of planimetry of photo-
graphs. The mechanisms underlying the increase in infarct size
induced by neonatal/adolescent exposure to SHS are unclear.
Figure 3. This profile plot shows percent infarct size. M-SHSna and
F-SHSna 5 young male and female rats, respectively, exposed to SHS in
the neonatal to adolescent period for 12 weeks; M-non-SHSna and
F-non-SHSna 5 young male or female rats, respectively, not exposed to
SHS in the neonatal to adolescent period; SHSu 5 young rats from
mother rats exposed to SHS in utero for 3 weeks; non-SHSu 5 young rats
from mother rats not exposed to SHS in utero. Data are presented as
mean value 6 SEM. The p values were derived from three-way ANOVA.
Figure 4. Nicotine (top) and cotinine (bottom) concentrations in
plasma are higher in SHS-exposed rats. SHSna 5 young rats exposed
to SHS in the neonatal to adolescent period for 12 weeks; non-
SHSna 5 young rats not exposed to SHS in the neonatal to adolescent
period. Data are presented as mean value 6 SEM. The p values were
derived from the Mann-Whitney rank-sum test.
Table 1. Effects of Second-Hand Smoke and Gender on Infarct Size
Groups
No. of
Rats
Infarct Mass/
Risk Area
(%)
Infarct Size/
LV Mass
(%)
Risk Area/
LV Mass
(%)
Female
SHSu/SHSna 8 56 6 3 33 6 2 58 6 2
Non-SHSu/SHSna 11 48 6 2 24 6 1 50 6 2
SHSu/non-SHSna 9 47 6 6 25 6 3 53 6 4
Non-SHSu/non-SHSna 13 36 6 3 19 6 2 52 6 2
Male
SHSu/SHSna 8 62 6 4 33 6 3 53 6 3
Non-SHSu/SHSna 6 68 6 7 40 6 6 57 6 5
SHSu/non-SHSna 6 62 6 3 33 6 3 58 6 6
Non-SHSu/non-SHSna 9 56 6 3 34 6 2 60 6 3
p Value
Gender , 0.001 , 0.001 0.0082
SHSna* 0.005 0.014 0.746
SHSu† 0.082 0.271 0.702
Gender 3 SHSna 0.469 0.388 0.182
Gender 3 SHSu 0.093 0.006 0.089
SHSna 3 SHSu 0.185 0.742 0.505
Gender 3 SHSu 3 SHSna 0.377 0.273 0.345
*Exposure to second-hand smoke (SHS) in the neonatal to adolescent period
for 12 weeks. †Exposure to SHS in utero for 3 weeks. Data are presented as
mean value 6 SEM. SHSu/SHSna 5 exposure to SHS in utero for 3 weeks and
in the neonatal to adolescent period of 12 weeks; SHSu/non-SHSna 5 exposure
to SHS in utero for 3 weeks; non-SHSu/SHSna 5 exposure to SHS in the
neonatal to adolescent period for 12 weeks; non-SHSu/non-SHSna 5 not
exposed to SHS (control group).
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A poorer collateral circulation in rats exposed to SHS is one
possibility.
Infarct size and gender. In previous infarct studies, we only
used female Sprague-Dawley rats because male rats had a
higher mortality due to arrhythmias during the occlusion and
reperfusion period. The present study provides the first com-
parison of the cardiovascular effects of SHS exposure between
male and female rats. We showed that the infarct size in male
rats was significantly higher than that in female rats, regardless
of SHS exposure. Male sex hormones, such as testosterone,
reduced endothelium-dependent relaxation and augmented
dysfunction associated with SHS (16). Female sex hormones,
such as estrogen, may also have some protective effect on
myocardial ischemia (29,30). A recent in vivo study from our
group (31) showed that the female sex hormone, 17b-estradiol,
attenuates endothelin-1–induced coronary vasoconstriction,
possible through an effect on the endothelin-A receptor. It is
possible that differences in infarct size between male and
female rats is due to sex hormone-related differences in
endothelin activity. However, as discussed earlier, the effect of
SHS of increasing infarct size was clearer in female rats.
Endothelin-1, angiotensin-2 and SHS exposure. Endothelin-1
is a potent vasoconstrictor agent with a potential role in
systemic hypertension and coronary artery disease (32). Smok-
ers tended to have higher endothelin-1 plasma levels within
10 min after the onset of smoking (33). Long-term smoking is
associated with an impaired endothelium-dependent vasodila-
tor response to low dose endothelin-1, and short-term smoking
enhances endothelin-1–induced vasoconstriction (34). In the
present study, endothelin-1 levels in plasma in neonatal rats
exposed to SHS were significantly higher than those in non-
SHS rats. The higher levels of endothelin-1 may increase
vasoconstriction and thus increase myocardial infarct size. The
mechanism of nicotine-induced vasoconstriction may be inde-
pendent of the release of endothelin or prostaglandin deriva-
tives from endothelial cells (35). Other tobacco smoke com-
ponents, such as carbon monoxide or tar, may be responsible
for the increase in plasma endothelin-1 in smokers (33). This
increase in the level of endothelin-1, a powerful vasoconstric-
tor and mitogen, may play an important part in the develop-
ment of atherosclerosis arising from smoking (36).
Angiotensin-2, as a vasoconstrictor, can accelerate the progres-
sion of vascular disease (37). In the present study,
angiotensin-2 plasma levels of neonatal rats exposed to SHS in
utero were significantly lower than those of rats not exposed to
SHS. The mechanism underlying this finding is unclear. It is
possible that SHS influences renal development, leading to
lower levels of renin and thus angiotensin. Alternatively, the
effect of SHS on the neonatal lung (23–25), or on other organs
that express levels of angiotensin-converting enzyme activity,
might account for our observation.
Clinical relevance. The rats were exposed to smoke from
the burning tip of the cigarette in the exposure chamber.
Therefore, they were exposed to a mixture of fresh and aged
sidestream smoke, which is the same mixture received by
people exposed to SHS. The exposure chamber we used had an
interior volume (3.6 m3) similar to that of an automobile sedan
(3.7 m3). If four passengers each smoked four cigarettes per
hour, that microenvironment would be similar to the one in the
present rat study. In our previous study, the average concen-
trations of air nicotine and carbon monoxide (1,103 mg/m3 and
92 ppm) in the SHS exposure chamber were about twofold
higher than those in human heavy smoking environments (50
to 500 mg/m3 and 5 to 50 ppm) (12). These exposure levels are
well below those that occur in active smokers. The duration of
Figure 5. This profile plot shows endothelin-1 concentrations in the
plasma of rats from the four groups. SHSna 5 rats exposed to SHS in
the neonatal period; non-SHSna 5 rats not exposed to SHS in the
neonatal period; SHSu 5 rats from mother rats exposed to SHS in
utero for 3 weeks; non-SHSu 5 rats from mother rats not exposed to
SHS in utero. Data are presented as mean value 6 SEM. The p values
were derived from two-way ANOVA.
Figure 6. This profile plot shows angiotension-2 concentrations in the
plasma of rats from the four groups. SHSna 5 rats exposed to SHS in
the neonatal period; non-SHSna 5 rats not exposed to SHS in the
neonatal period; SHSu 5 rats from mother rats exposed to SHS in
utero for 3 weeks; non-SHSu 5 rats from mother rats not exposed to
SHS in utero. Data are presented as mean value 6 SEM. The p values
were derived from two-way ANOVA.
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exposure to SHS in the present study was only 360 h spread
over 12 weeks (6 h/day, 5 days/week). Compared with many
chemical toxicology studies that involve doses several orders of
magnitude above ambient levels, the levels of exposure of SHS
we used were realistic.
The plasma nicotine concentrations in the present study
were 39 6 5 ng/ml. By comparison, rats receiving 4 mg/kg per
day of nicotine, a total dose equivalent to ;1 pack of cigarettes
per day, have plasma nicotine levels ;250 ng/ml (38,39), six
times the levels we observed. Thus, the levels of nicotine we
observed in our rats are comparable to what would be expected
from a heavy level of passive smoking, as opposed to active
smoking. The duration of SHS exposure, however, was short,
even compared with a rat’s lifetime (about 2 to 3 years) (40).
Myocardial infarct size significantly increased with just 360 h of
SHS exposure spread over 12 weeks. This is equivalent to 2%
of the projected lifespan. Assuming a human lifespan of 75
years, an equivalent period of exposure to SHS would be 6 h
per day for 6 years. Thus, these data may well have clinical
relevance.
Conclusions. Exposure to SHS in pregnant rats signifi-
cantly increased birth mortality and decreased neonatal body
weight. Exposure to SHS in the neonatal to adolescent period
and male gender increased myocardial infarct size in a young
rat model of ischemia and reperfusion. These results are
consistent with epidemiologic studies demonstrating that SHS
increases the risk of death due to heart disease.
We are grateful to Jaw-kang Chang, PhD and Yun-tao Zhao, BS at Phoenix
Pharmaceuticals, Inc., Mountain View, California for excellent technical assis-
tance in the measurement of endothelin-1 and angiotensin-2.
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